A clinical trial involving NNC0174-1213, related to cagrilintide research, was updated to completed status as of August 25, 2026. The study, registered as NCT06719011 and titled "A Study on How NNC0174-1213 Works in People With Overweight or Obesity," is listed as a Phase 1 trial. Cagrilintide remains classified as an unapproved compound under research investigation. The trial's status update reflects only that the study has concluded its listed phase, according to the registry entry. No results, findings, or outcome data are included in this update. The registry record does not specify efficacy, safety conclusions, or comparative data associated with the study. This brief reflects only the status change recorded in the trial registry as of the listed date. Readers interested in the broader context of cagrilintide research and its current regulatory classification can consult the compound overview for additional background.
Cagrilintide-Related Study NCT06719011 Marked Completed, Phase 1
See the full cagrilintide overview
Source: https://clinicaltrials.gov/study/NCT06719011